Reykjavik (IFN) Icelandic pharmaceutical company Actavis Group has received approval from the U.S. Food and Drug Administration to market Alprazolam ER tablets, the company said on Wednesday.
The company said distribution of the product will commence in coming weeks. Alprazolam ER tablets, the generic equivalent of Pfizers Xanax XR tablets, will be available in 0.5 mg, 1 mg, 2 mg, and 3 mg strengths.
Alprazolam ER tablets are indicated for the treatment of anxiety and panic disorder.
Annual sales of Alprazolam ER tablets in the U.S. were around USD53.9 million in 2006, according to IMS Health data.
(END)
Icelandic Financial News (IFN) is available on Factiva, a joint venture between Reuters and Dow Jones Newswires, FT.COM, LexisNexis, Comtex, Gale and Thomson via the Nordic Business Report.
